报价延迟最少15分钟:2025/08/26 17:17 EDT
盘后时段
|
||||
|
168.02 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
168.02
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.92/-0.55
|
|
企业价值
6.04B
|
| 资产负债 |
|
每股账面净值
3.23
|
| 现金流量 |
|
现金流量率
0.01
|
| 损益表 |
|
收益
591.84M
|
|
每股收益
14.72
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/26 17:17 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-clearedand CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias. |
